Tempus AI, Inc. logo

Tempus AI, Inc. (TEMD)

Market Closed
10 Aug, 20:00
BCBA BCBA
$
4. 79
+0.34
+7.7615%
$
- Market Cap
- P/E Ratio
- Div Yield
2,291 Volume
- Eps
$ 4.45
Previous Close
Add Transaction
Day Range
4.63 4.88
Year Range
3.48 6.04
Want to track TEMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

TEMD closed today higher at $4.79, an increase of 7.7615% from yesterday's close, completing a monthly decrease of -8.0614% or -$0.42. Over the past 12 months, TEMD stock lost -14.4643%.
TEMD is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on BCBA (USD).

TEMD Chart

Tempus AI, Inc. (TEMD) FAQ

What is the stock price today?

The current price is $4.79.

On which exchange is it traded?

Tempus AI, Inc. is listed on BCBA.

What is its stock symbol?

The ticker symbol is TEMD.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Tempus AI, Inc. ever had a stock split?

No, there has never been a stock split.

Tempus AI, Inc. Profile

Technology Hardware, Storage & Peripherals Industry
Information Technology Sector
Eric Lefkofsky CEO
BCBA Exchange
- ISIN
US Country
3,800 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Tempus AI, Inc. stands as a vanguard healthcare technology company, specializing in delivering cutting-edge diagnostic solutions. Established in 2015 and based in Chicago, Illinois, its operations encompass a comprehensive range of molecular and anatomic pathology tests. Initially known as Tempus Labs, Inc., the company underwent a rebranding to Tempus AI, Inc. in January 2023. Its offerings are designed to support healthcare providers, pharmaceutical entities, biotechnology firms, researchers, and other third-party organizations. Its mission revolves around the fusion of clinical data and artificial intelligence to forge advancements in healthcare outcomes.

Products and Services

Tempus AI, Inc. has curated a diverse portfolio of products and services, each tailored to address various aspects of healthcare diagnostics and research:

  • Next Generation Sequencing Diagnostics: Leveraging comprehensive genomic profiling to aid in the identification of DNA mutations responsible for cancers, guiding personalized treatment plans.
  • Polymerase Chain Reaction (PCR) Profiling: Enabling rapid detection and identification of genetic material from a specific organism, useful in diagnosing infectious diseases, among others.
  • Molecular Genotyping: Provides essential data for understanding genetic predispositions to diseases, facilitating preventive healthcare strategies.
  • Insights: Offers a vast library of de-identified clinical, molecular, and imaging data, coupled with a suite of analytical services. It provides pharmaceutical and biotechnology companies with valuable data analytics capabilities, by employing advanced analytical and cloud-compute technologies.
  • Trials: A service designed to match clinical trials with suitable candidates, thus accelerating the drug development process for pharmaceutical companies.
  • Next; Algos: This suite presents algorithmic tests specifically in the field of oncology, enhancing the speed and accuracy of cancer diagnosis and treatment planning.
  • Hub: A comprehensive platform for healthcare providers, facilitating easy ordering, management, and receipt of tests and patient results through both desktop and mobile interfaces.
  • Lens: Exclusively for researchers and scientists, this platform allows the exploration, access, and analysis of Tempus's rich data sets, fostering innovation in medical research.

Contact Information

Address: 600 West Chicago Avenue
Phone: 800 976 5448